DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma

Phase 1

Completed

Conditions: Nasopharyngeal Carcinoma

Interventions: Biological: Epstein-Barr virus-specific adoptive T-cells immunotherapy

First Posted Date: 2007-02-05

Last Posted Date: 2017-04-18

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 28

Registration Number: NCT00431210

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Natural History Study of Patients With Chronic Myelogenous Leukemia

Completed

Conditions: Leukemia

First Posted Date: 2007-02-01

Last Posted Date: 2017-01-02

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 48

Registration Number: NCT00429910

Locations: 🇺🇸
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States

Banking of Chronic Lymphocytic Leukemia Tumor Cells for Vaccine Generation

Phase 1

Completed

Conditions: Chronic Lymphocytic Leukemia

Interventions: Procedure: Leukemia cell harvest

First Posted Date: 2007-01-29

Last Posted Date: 2020-04-08

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 65

Registration Number: NCT00428233

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

GM-CSF Vaccinations After Allogeneic Blood Stem Cell Transplantation in Patients With Advanced Myeloid Malignancies

Not Applicable

Completed

Conditions: Myelodysplastic Syndrome RAEB-I or RAEB-II
Refractory CML Myeloid Blast Crisis
Refractory Acute Myeloid Leukemia

First Posted Date: 2007-01-24

Last Posted Date: 2022-02-11

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 28

Registration Number: NCT00426205

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Pemetrexed in Patients With Advanced Neuroendocrine Tumors

Phase 2

Completed

Conditions: Neuroendocrine Tumors

First Posted Date: 2007-01-19

Last Posted Date: 2010-08-12

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 32

Registration Number: NCT00424723

Locations: 🇺🇸
Dana-Farber Cancer Center, Boston, Massachusetts, United States

Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma

Phase 2

Completed

Conditions: Mucosal Melanoma
Acral/Lentiginous Melanoma
Chronically Sun Damaged Melanomas

Interventions: Drug: Imatinib

First Posted Date: 2007-01-19

Last Posted Date: 2016-12-08

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 24

Registration Number: NCT00424515

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
H. Lee Moffitt Cancer Center, Tampa, Florida, United States

and more 2 locations

Combination Bortezomib and Rituximab in Patients With Waldenstrom's Macroglobulinemia (WM)

Phase 2

Completed

Conditions: Waldenstrom's Macroglobulinemia

Interventions: Drug: Bortezomib
Drug: Rituximab

First Posted Date: 2007-01-17

Last Posted Date: 2020-10-27

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 63

Registration Number: NCT00422799

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Perifosine in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia

Phase 2

Completed

Conditions: Waldenstrom's Macroglobulinemia

Interventions: Drug: Perifosine

First Posted Date: 2007-01-17

Last Posted Date: 2017-12-26

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 37

Registration Number: NCT00422656

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Oxaliplatin, Gemcitabine and Bevacizumab in Women With Recurrent Mullerian Carcinoma

Phase 2

Terminated

Conditions: Ovarian Cancer
Fallopian Tube Cancer
Primary Peritoneal Cancer

Interventions: Drug: Gemcitabine
Drug: Oxaliplatin
Drug: Bevacizumab

First Posted Date: 2007-01-04

Last Posted Date: 2014-06-19

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 19

Registration Number: NCT00418093

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

RAD001 in Previously Treated Patients With Metastatic Pancreatic Cancer

Phase 2

Completed

Conditions: Pancreatic Cancer

Interventions: Drug: RAD001

First Posted Date: 2006-12-08

Last Posted Date: 2014-08-11

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 33

Registration Number: NCT00409292

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy